FAQ: Izotropic Corporation's AI Integration into Breast CT Imaging System
Summary
Izotropic Corporation has integrated its proprietary AI-based machine-learning reconstruction algorithm into its IzoView Breast CT Imaging System, developed with Johns Hopkins University, to improve image quality while maintaining low radiation doses and addressing clinical efficiency challenges in breast cancer screening.
What is the main announcement from Izotropic Corporation?
Izotropic has integrated its proprietary AI-based machine-learning reconstruction algorithm into its flagship IzoView Breast CT Imaging System to improve image quality while maintaining low radiation doses.
Why is this AI integration significant for breast cancer screening?
It addresses image noise at its source, offering a potential breakthrough for clinical efficiency compared to conventional denoising methods that are limited by speed and workflow practicality.
How does Izotropic’s AI algorithm differ from conventional methods?
Unlike conventional methods such as Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR), Izotropic’s approach addresses image noise at its source rather than using traditional denoising techniques.
Who collaborated with Izotropic on developing this AI algorithm?
The algorithm was developed in collaboration with The Johns Hopkins University School of Medicine.
What is the name of Izotropic’s breast imaging system?
The system is called the IzoView Breast CT Imaging System.
Where can investors find more information about Izotropic Corporation?
More information can be found on the company’s website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.
How can I stay updated on Izotropic’s latest news?
The latest news and updates are available in the company’s newsroom at https://ibn.fm/IZOZF.
What are the stock symbols for Izotropic Corporation?
Izotropic trades under CSE: IZO, OTCQB: IZOZF, and FSE: 1R3.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 186035